ASOs targeting p21 has been already applied in breast cancer [211,212], colorectal cancer [190], glioma [191], myeloid leukemia [110] and renal cell carcinoma cell lines [213] showing growth arrest and/or apoptosis. Here, CDKN1A is linked to hereditary clear cell renal cell carcinoma.